Evidence map›Paper›PMID 34331713›Full record

ArticleJournal of medical virology2021

Performance assessment of seven SARS-CoV-2 IgG enzyme-linked immunosorbent assays.

Ketki Deshpande, Ullas Pt, Ojas Kaduskar, Neetu Vijay, Aparna Rakhe, Shankar Vidhate, Kirtee Khutwad, Gururaj Rao Deshpande, Bipin Tilekar, Sanskruti Saka and 10 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Community seroprevalence and risk factors for SARS-CoV-2 infection in different subpopulations in Vellore, India, and their implications for future prevention.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Ketki DeshpandeICMR-National Institute of Virology, Pune, Maharashtra, India.
Ullas PtICMR-National Institute of Virology, Pune, Maharashtra, India.
Ojas KaduskarICMR-National Institute of Virology, Pune, Maharashtra, India.
Neetu VijayVirology Unit, Indian Council of Medical Research, New Delhi, India.
Aparna RakheICMR-National Institute of Virology, Pune, Maharashtra, India.
Shankar VidhateICMR-National Institute of Virology, Pune, Maharashtra, India.
Kirtee KhutwadICMR-National Institute of Virology, Pune, Maharashtra, India.
Gururaj Rao DeshpandeICMR-National Institute of Virology, Pune, Maharashtra, India.
Bipin TilekarICMR-National Institute of Virology, Pune, Maharashtra, India.
Sanskruti SakaICMR-National Institute of Virology, Pune, Maharashtra, India.
Kshitija GadekarICMR-National Institute of Virology, Pune, Maharashtra, India.
Roshni PatilICMR-National Institute of Virology, Pune, Maharashtra, India.
Pragya YadavMaximum Containment Laboratory, ICMR-National Institute of Virology, Pune, India.
Varsha PotdarHuman Influenza Group, ICMR-National Institute of Virology, Pune, India.ORCID https://orcid.org/0000-0002-7535-7878
Yogesh GuravEpidemiology Group, ICMR-National Institute of Virology, Pune, India.
Priyanka GuptaVirology Unit, Indian Council of Medical Research, New Delhi, India.
Harmanmeet KaurVirology Unit, Indian Council of Medical Research, New Delhi, India.
Jitendra NarayanVirology Unit, Indian Council of Medical Research, New Delhi, India.
Gajanan SapkalICMR-National Institute of Virology, Pune, Maharashtra, India.
Priya AbrahamICMR-National Institute of Virology, Pune, Maharashtra, India.
ICMR-National Institute of Virology · INIndian Council of Medical Research · IN

Funding

ICMR-National Institute of Virology, Pune
6 · The paper itself

Abstract

The pandemic of COVID-19 has caused enormous fatalities worldwide. Serological assays are important for detection of asymptomatic or mild cases of COVID-19, and sero-prevalence and vaccine efficacy studies. Here, we evaluated and compared the performance of seven commercially available enzyme-linked immunosorbent assay (ELISA)s for detection of anti-severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) immunoglobulin G (IgG). The ELISAs were evaluated with a characterized panel of 100 serum samples from qRT-PCR confirmed COVID-19 patients, collected 14 days post onset disease, 100 SARS-CoV-2 negative samples and compared the results with that of neutralization assay. Results were analysed by creating the receiver operating characteristic curve of all the assays in reference to the neutralization assay. All kits, were found to be suitable for detection of IgG against SARS-CoV-2 with high accuracy. The DiaPro COVID-19 IgG ELISA showed the highest sensitivity (98%) among the kits. The assays demonstrated high sensitivity and specificity in detecting the IgG antibodies against SARS-CoV-2. However, the presence of IgG antibodies does not always correspond to neutralizing antibodies. Due to their good accuracy indices, these assays can also aid in tracing mild infections, in cohort studies and in pre-vaccine evaluations.

Indexed as

Enzyme-Linked Immunosorbent AssayAntibodies, ViralCOVID-19COVID-19 TestingHumansImmunoglobulin GNeutralization TestsReagent Kits, DiagnosticReproducibility of ResultsReverse Transcriptase Polymerase Chain ReactionSARS-CoV-2Sensitivity and SpecificityAntibodies, ViralImmunoglobulin GReagent Kits, DiagnosticCOVID-19ELISAIgG antibody assayROCSARS-CoV-2

Identifiers

PMID34331713
PMCPMC8426713
OpenAlexW3183943426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.